December 2024

New Products

• Bretovameran (Comirnaty JN.1) is a nucleoside-modified messenger RNA formulated in lipid nanoparticles, which enable delivery of the non-replicating RNA into host cells to direct transient expression of the SARS‑CoV‑2 spike (S) antigen. Comirnaty elicits both neutralising antibody and cellular immune responses to the antigen, which may contribute to protection against COVID‑19. Comirnaty JN.1 is indicated for active immunisation to prevent COVID‑19 in individuals 6 months of age and older in accordance with official recommendations. Comirnaty JN.1 suspension for injection contains bretovameran 10 mcg per 0.3 mL (single dose vial with light blue cap or six‑dose vial with dark blue cap) or 30 mcg per 0.3 mL (single dose glass/ plastic prefilled syringe or single dose vial with light grey cap or six‑dose vial with dark grey cap) and is available in packs of 10. Comirnaty JN.1 concentrate for suspension for injection contains bretovameran 3 mcg per 0.2 mL (10‑dose vial with maroon cap) or 3 mcg per 0.3 mL (3‑dose vial with yellow cap) or 10 mcg per 0.2 mL (10‑dose vial with orange cap) and is available in packs of 10 or 195.

New Indications

• Adalimumab (rch) (Humira) is now indicated for the treatment of chronic non-infectious anterior uveitis in paediatric patients 2 years of age and older who have had an inadequate response to or are intolerant to conventional therapy, or in whom conventional therapy is inappropriate.
   
• Kit for Ga-68 Glu-urea-Lys(ahx)-hbed-CC radiopharmaceutical preparation (Illuccix) is now indicated for the selection of patients with metastatic prostate cancer in whom Lu‑177 vipivotide tetraxetan prostate-specific membrane antigen-directed therapy is indicated.

This list is a summary of only some of the changes that have occurred over the last month.
Before prescribing, always refer to the full product information.